Sansure Biotech(SH:688289)2022-04-18 16:00Financial Performance - The net profit attributable to shareholders for 2021 was CNY 2,242,696,395.58, with a distributable profit of CNY 3,780,104,914.61 as of December 31, 2021[7]. - The total cash dividends distributed in 2021 amounted to CNY 647,497,083.85, representing 28.87% of the net profit attributable to ordinary shareholders[10]. - The company's operating revenue for 2021 was approximately ¥4.51 billion, a decrease of 5.22% compared to ¥4.76 billion in 2020[34]. - The net profit attributable to shareholders for 2021 was approximately ¥2.24 billion, down 14.29% from ¥2.62 billion in 2020[34]. - The net cash flow from operating activities for 2021 was approximately ¥1.88 billion, down 28.96% from ¥2.64 billion in 2020[34]. - The gross margin for the year was reported at 60%, an increase from 55% in the previous year[20]. - The company achieved total operating revenue of CNY 4,514.54 million, a slight decrease of 5.22% compared to the previous year[38]. - The net profit attributable to the parent company was CNY 2,242.70 million, down 14.29% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 2,150.54 million, a decrease of 17.05%[38]. - Operating costs increased by 31.87% to CNY 1,279,045,408.93, compared to CNY 969,952,932.60 in the previous year[151]. Dividend and Profit Distribution - The proposed cash dividend is CNY 3.75 per 10 shares, totaling CNY 148,203,262.88, subject to shareholder approval[7]. - The board of directors has approved the annual profit distribution plan, pending shareholder meeting approval[7]. - The company emphasizes the importance of protecting investor rights and aims for stable and continuous profit distribution[10]. Research and Development - Research and development expenses reached CNY 187.50 million, a significant increase of 126.53% compared to the previous year, representing 4.15% of operating revenue[38]. - The company registered 132 new domestic and international product approvals during the reporting period, enhancing its product portfolio[39]. - The company is actively involved in research and development, focusing on new product innovations and expanding into public health and disease prevention sectors[62]. - The company increased R&D investment to 187.50 million yuan, a significant year-on-year growth of 126.53%[109]. - R&D expenditure accounted for 4.15% of total revenue, up by 2.41 percentage points from the previous year[109]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2023[20]. - The company has established overseas subsidiaries in Indonesia, France, the UK, and the Philippines, and set up offices in Thailand and Brazil to expand its global market presence[56]. - The company is focusing on enhancing its online sales platform, with a target to increase online sales by 35% in the upcoming year[20]. - The company aims to enhance its market share by leveraging distributors' networks and regional advantages to identify potential customers[75]. - The company is actively expanding its international market presence, particularly in the context of COVID-19 testing products, which have seen sustained demand[80]. Product Development and Innovation - New product development includes the launch of a next-generation nucleic acid testing kit, which is expected to enhance testing efficiency by 40%[20]. - The company has developed over 400 high-performance products and offers more than 2,200 quality testing services, focusing on various medical fields including viral hepatitis, reproductive infections, and cancer early screening[62]. - The company launched six respiratory pathogen nucleic acid test kits and received NMPA Class III medical device registration, expanding its product offerings in the respiratory disease detection market[90]. - The company developed a rapid COVID-19 antigen detection product with a testing time of just 10 minutes, achieving industry-leading sensitivity and specificity[104]. - The company is developing a new generation of miniaturized high-throughput sequencing platforms for various applications, including pathogen detection and cancer screening[117]. Operational Risks and Challenges - The company acknowledges various operational risks and has outlined corresponding mitigation strategies in the report[5]. - The company faces risks related to intensified market competition, particularly from multinational corporations like Roche and Abbott[141]. - Future changes in tax incentives and government subsidies could adversely affect the company's operating performance and profitability[145]. Financial Health and Assets - The net assets attributable to shareholders at the end of 2021 were approximately ¥6.37 billion, an increase of 34.21% from ¥4.75 billion at the end of 2020[34]. - The total assets at the end of 2021 were approximately ¥7.09 billion, an increase of 29.99% from ¥5.45 billion at the end of 2020[34]. - The company's total assets at the end of 2021 were CNY 7,090.37 million, an increase of 29.99% year-on-year, and the equity attributable to shareholders of the parent company grew by 34.21% to CNY 6,368.91 million[39]. - The company’s total liabilities decreased by 43.35% to ¥688,590,633.45, primarily due to the repayment of borrowings[179]. Sales and Revenue - The company reported a significant increase in the export value of its main in vitro diagnostic products, reaching $13.093 billion in 2021, a year-on-year growth of 157.37%[80]. - Domestic revenue reached ¥2,634,907,741.27, representing a year-on-year increase of 21.28%[158]. - Overseas revenue was ¥1,706,775,081.94, down 29.63% year-on-year due to changes in overseas pandemic policies[158]. Quality and Compliance - The company has passed international quality system certifications such as ISO13485 and ISO9001, ensuring strict quality management in production and inspection[71]. - The company has established strict confidentiality measures to protect its core technologies from leakage and theft[140].